16 production sites on 5 continents.
Affiliates or offices in 77 countries.
Products marketed in more than 165 countries.
|Approximately 42,000 employees (March 2017).
Approximately 42% of employees are located in Denmark (17,804) and 58% in the rest of the world (North America 6,321 and in International Operations, 4,296 in Europe, 6,321 in Africa, Asia, Middle East & Oceania, 4,371 Region China, 1,777 in Latin America and 1,179 in Japan & Korea).
|20% within research and development
32% in production and production administration
36% in international sales and marketing
12% in administration
According to applicable law, only health care professionals are allowed to access product information on our site. Please find the information under Health Care Professionals.
For patient and disease information, including pens and needles, please look under Patients.
28,452 million Danish kroner Q1 2017
Sales by business segment
Diabetes and obesity care total:
23,761 million Danish kroner
4,691 million Danish kroner
Sales by region
North America Operations:
14,940 million Danish kroner
USA: 14,402 million Danish kroner
13,512 million Danish kroner
Region Europe: 5,226 million Danish kroner
Region AAMEO: 2,964 million Danish kroner
Region China: 3,060 million Danish kroner
Region Japan & Korea: 1,467 million Danish kroner
Region Latin America: 795 million Danish kroner
Novo Nordisk A/S
CVR nr. 24 25 67 90